Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway

BACKGROUND: Gefitinib-resistance is a primary obstacle for the treatment of non-small-cell lung cancer (NSCLC). It has been shown that tanshinone IIA (Tan IIA) could induce apoptosis of NSCLC cells. However, the role of combination of gefitinib with Tan IIA on gefitinib-resistance NSCLC cells remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rui, Luo, Zhilin, Zhang, Hong, Wang, Tianhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844214/
https://www.ncbi.nlm.nih.gov/pubmed/31807016
http://dx.doi.org/10.2147/OTT.S221228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844214/
https://www.ncbi.nlm.nih.gov/pubmed/31807016
http://dx.doi.org/10.2147/OTT.S221228

Ejemplares similares